NORTH ANDOVER, MASSACHUSETTS, USA, July 5, 2016 – Bach Pharma Inc., a Delaware Corporation, today announced the appointment of Kelly Blackburn as Chief Executive Officer and as a member of the Bach Pharma Board of Directors. Ms. Blackburn will lead the company into their next stage of development, bringing the company’s lead candidate, GVT®, into the clinic.
“I am excited for the opportunity to advance this company to the next stage” said Kelly Blackburn, CEO, Bach Pharma. “I believe there is great potential to improve patients’ lives with these therapeutics. With their lead candidate, GVT, Bach Pharma is on the cutting edge of development for the treatment of life threatening neurological diseases.”
Bach Pharma also announced that Mark O. Henry will serve as Chief Financial Officer, transitioning from his role as CEO. Mr. Henry expressed his enthusiasm regarding the addition of Ms. Blackburn to the team, “Kelly is an accomplished executive in the healthcare industry who brings deep experience in running pharmaceutical operations to this role. We are thrilled to have her on board.”
Ms. Blackburn was previously Vice President of Clinical Affairs at aTyr Pharma in San Diego, California where as a member of the Executive Leadership Team, she was responsible for the oversight of clinical and regulatory plans for all programs. Ms. Blackburn has worked in several other pharmaceutical companies including Vertex pharmaceuticals where she led the operations for their portfolio. Her successes include approvals for transformative therapies in Cystic Fibrosis, Hepatitis C and Multiple Myeloma.
ABOUT BACH PHARMA
Bach Pharma, Inc., (BACH), a privately held pharmaceutical company, is a global leader in the development of revolutionary phthalazinedione-based therapeutics to treat life threatening diseases. BACH is targeting the development of therapies for life threatening oxidative stress-related diseases with the goal to dramatically improve patients’ lives and reduce the cost of global health care.
The company’s lead candidate GVT is a novel cytoprotective agent that has powerful anti-oxidant and anti-inflammatory properties. Research has shown that GVT can reverse oxidative stress, restore intracellular redox homeostasis and quell inflammation. GVT has the potential to treat various serious diseases of the central nervous and immune systems. Bach has intellectual property for GVT as well as multiple derivatives. The leading program will be focused on severe rare neurological diseases.
Bach is a proud member of the MassBio Council and a host company for the Massachusetts Life Science Center Internship Challenge.
Media Contact: Mark O. Henry, CFO